CALI: Rega marang dodolan CalciMedica Inc
CalciMedica, Inc. (CALI) operates as a biopharma startup, investing all capital into research without generating revenue. The price-to-sales multiple clearly demonstrates this lack of sales, where the level of 0.00 is the current value. Geopolitical tensions and sanctions complicate the logistics of biomaterials, yet professional management is successfully adapting the company's structure based on the results of anti-inflammatory drug trials.
Rincian analitis perusahaan CalciMedica, Inc. (CALI)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas CalciMedica, Inc.|CALI - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas calcimedica.com|CALI - Gunggung utang perusahaan|Utang-utang marang aset resik CalciMedica Corp|CALI - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan CalciMedica|Likuiditas darurat calcimedica.com
- data bathi bisnis lan rasio investasi:
CALI - Bathi resik|Prakiraan bathi resik CalciMedica, Inc.|CALI - Pangali P/E|Kapitalisasi marang proyeksi bathi calcimedica.com|CALI - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan CalciMedica Corp|CALI - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) CalciMedica|CALI - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan calcimedica.com|CALI - Wutah bathi ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep CalciMedica, Inc.
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:CALI, CalciMedica Inc
The multiple compares the market value of CalciMedica, Inc. (CALI) to its sales volume, allowing for an assessment of the asset's overvaluation relative to its generated cash flow. For the biotech sector, characterized by high patent scalability, this price-to-sales ratio reflects market expectations for the global implementation of the therapy, helping investors timely identify the risk of purchasing an overvalued business.
Pesaing CalciMedica, Inc.
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA Bio - Multiplikator P/S|Protagonist Corp (PTGX) - Kapitalisasi marang pendapatan|IMVT: Multiplikator P/S|kiniksa.com (KNSA) - Multiplikator P/S|Rasio rega marang pendapatan Grifols|Rasio rega marang pendapatan ADPT|Multiplikator P/S CLDX|Kapitalisasi marang pendapatan Aurinia Corp AUPH|Multiplikator P/S BCRX (BioCryst)|Koefisien rega marang pendapatan veratx.com (VERA)|DNTH - Rasio rega marang pendapatan|Pharvaris NV (PHVS) - Kapitalisasi marang pendapatan|ABCL: Multiplikator P/S|Rega marang dodolan Tourmaline (TRML)|PGEN (Precigen, Inc.) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan PHAR (pharming.com)|Multiplikator P/S NKTR|Koefisien rega marang pendapatan Upstream Bio, Inc.|Multiplikator P/S ZBIO (Zenas Biopharma, Inc.)|IMNM - Kapitalisasi marang pendapatan|Gossamer Bio, Inc. - Multiplikator P/S|KALV - Multiplikator P/S|SEPN (Septerna) - Kapitalisasi marang pendapatan|Pieris Pharma - Rasio kapitalisasi pasar marang pendapatan|SVRA (Savara Corp) - Multiplikator P/S|Rigel Corp (RIGL) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan AnaptysBio, Inc. (ANAB)|astriatx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ENGN (enGene)|RAPT - Kapitalisasi marang pendapatan|JBIO: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Aclaris Therapeutics, Inc ACRS|KYTX: Multiplikator P/S|Kapitalisasi marang pendapatan tizianalifesciences.com|CABA (Cabaletta Bio) - Multiplikator P/S|Multiplikator P/S Ventyx Biosciences Inc.|Rasio rega marang pendapatan Theratechnologies Inc (THTX)|Rasio rega marang pendapatan AVTX (Avalo Therapeutics Inc)|Multiplikator P/S ELDN (Eledon Pharmaceuticals)|Koefisien rega marang pendapatan agenusbio.com (AGEN)|CLYM - Rasio rega marang pendapatan|Rasio rega marang dodolan ZURA|ATYR: Multiplikator P/S|Adagene Inc. - Rasio kapitalisasi pasar marang pendapatan|IMA (ImageneBio) - Multiplikator P/S|Multiplikator P/S Shattuck Therapeutics|Rasio rega marang pendapatan Equillium, Inc. (EQ)|CNTB (connectbiopharm.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Immunic IMUX|ATRA - Kapitalisasi marang pendapatan|InflaRx GmbH - Multiplikator P/S|XFOR - Multiplikator P/S|ACET (adicetbio.com) - Kapitalisasi marang pendapatan|Celularity - Rasio kapitalisasi pasar marang pendapatan|INMB (INmune Bio Corp) - Multiplikator P/S|Barinthus Biotherapeutics Corp (BRNS) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Kezar Life Sciences (KZR)|Kapitalisasi marang pendapatan sabbiotherapeutics.com SABS|Rasio rega marang pendapatan Akari Therapeutics Plc AKTX|ENLV - Kapitalisasi marang pendapatan|QTTB: Kapitalisasi marang pendapatan|GOVX - Multiplikator P/S|Edesa Biotech, Inc. (EDSA) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan IBIO|CARM (Carisma Therapeutics Inc) - Multiplikator P/S|Rega marang dodolan XTL Biopharmaceuticals Ltd XTLB|Multiplikator P/S BOLT|Kapitalisasi marang pendapatan hcwbiologics.com HCWB|Multiplikator P/S APVO (Aptevo Therapeutics Inc.)|Multiplikator P/S AIM ImmunoTech, Inc. AIM|ADTX - Rasio rega marang pendapatan|GRI: Rasio rega marang pendapatan|XRTX: Multiplikator P/S|Kapitalisasi marang pendapatan Vyome Therapeutics|REVB (Revelation Biosciences) - Multiplikator P/S|indaptusrx.com (INDP) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Scinai Immunotherapeutics Ltd. (SCNI)|Kapitalisasi marang pendapatan affimed.com AFMD|Multiplikator P/S ALLK (Allakos)|HOOKIPA Pharma, Inc. (HOOK) - Rega marang dodolan|IGM Bio - Multiplikator P/S|ITOS (iteostherapeutics.com) - Rasio kapitalisasi marang pendapatan|OCEA: Multiplikator P/S|TCBP - Koefisien rega marang pendapatan|THRD (Third Harmonic Bio, Inc) - Multiplikator P/S
